Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The company discontinues the Lag3 project in lung cancer.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
